Genomate Health

Genomate Health is a biotechnology startup founded in 2022 and based in the United States. The company's slogan, "The right drug. The first time. Every time.™", encapsulates its focus on AI-powered clinical decision support for precision oncology. Genomate Health specializes in developing AI-powered computational tools for personalized medicine, aiming to assist physicians in making optimal personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases. The company's flagship product, Genomate™ MTC (Molecular Treatment Calculator), stands out as the first computational AI solution clinically proven to improve personalized N-of-1 treatment decisions in precision oncology. It automates data compilation, evaluation, and synthesis in a knowledge model, enabling standardized, personalized treatment decisions based on the totality of available molecular information. In its recent funding round, Genomate Health secured a noteworthy $5.73M in Seed Round investment from Oktogon Ventures, Dr. Gyözö János Drozdy, and Jared Schrieber on 01 October 2022. The startup is strategically partnering with cancer centers, molecular diagnostic companies, insurance companies, health funds, and pharma companies to advance access to effective targeted therapies for cancer patients worldwide. The innovative approach of Genomate Health in leveraging AI for precision oncology and its successful track record in attracting substantial investment make it a compelling player in the biotechnology and healthcare industries. As the company positions itself at the forefront of personalized medicine, it presents an intriguing opportunity for venture capital firms seeking to invest in groundbreaking advancements within the healthcare sector.